Shares of drug-maker Merck (MRK) stalled on the charts at the early 2024 pivot breakdown level. The equity is also losing steam around resistance at the $120 zone, with the final decent call open interest (OI) level at the 125 strike.

BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.

Pre-Market Stock Futures: Futures are trading lower as we wrap up the holiday-shortened week that gave us a little taste of just about everything. While Walmart posted results that beat expectations, its forward guidance and outlook fell short of Wall Street's expectations, and the stock was down from the opening bell to the close. All... Here Are Friday's Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 at Increased Risk for Severe RSV Over Two RSV Seasons.

Merck & Co. Inc. (NYSE: MRK) on Wednesday announced a strategic collaboration with Mayo Clinic to leverage artificial intelligence (AI) and advanced analytics in drug discovery.

RAHWAY, N.J., & ROCHESTER, Minn.--(BUSINESS WIRE)--Merck and Mayo Clinic today announced a R&D agreement to apply artificial intelligence (AI), advanced analytics and data to support drug discovery.

There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That's a fancy way of saying that prosperity is concentrated in some U.S. states more than in others. As a result, a handful of America's 50 states have more millionaires than others. By the process... This State Has More Millionaires Per Capita Than Any Other.

Crestwood Advisors Group LLC cut its holdings in Merck and Co., Inc. (NYSE: MRK) by 4.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,773 shares of the company's stock after selling 4,673 shares during the quarter. Crestwood Advisors Group

Merit Financial Group LLC raised its position in Merck and Co., Inc. (NYSE: MRK) by 13.3% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 140,743 shares of the company's stock after buying an additional 16,545 shares during the period. Merit Financial

MRK outlines solid long-term outlook with more than $70B opportunity beyond Keytruda LOE, backed by pipeline progress, new product launches and M&A deals.